Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance

PHIBRO ANIMAL HEALTH CORP

2026-Q2 EPS reported $1.32 revenue$737,803,000

Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.
Adjusted diluted EPS $0.87 (+58% YoY); adjusted EBITDA $68.1M (+41% YoY).
Animal Health sales +26% to $290M, driven by $57.5M incremental MFA portfolio revenue.
FY2026 guidance raised: net sales $1.45-1.50B, adjusted EBITDA $245-255M, adjusted EPS $2.93-3.10.
Gross margin improved 260 bps to 35.5%; 3.1x gross leverage ratio; free cash flow $47.3M TTM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.